genel tıp derg

Genel Tıp Dergisi

2602-3741

Selcuk University

10.54005/geneltip.1807952

Clinical Sciences (Other)

Klinik Tıp Bilimleri (Diğer)

Prognostic Value of TAPSE/sPAP Ratio, RV S′ Velocity, and RV S′/sPAP Ratio in Hospitalized Patients with COVID-19: A Retrospective Echocardiographic Analysis

Hastaneye Yatırılan COVID-19 Hastalarında TAPSE/sPAP Oranı, RV S′ Hızı ve RV S′/sPAP Oranının Prognostik Değeri: Retrospektif Bir Ekokardiyografik Analiz

https://orcid.org/0000-0002-8930-3651

Ülgen Kunak

Ayşegül

UNIVERSITY OF HEALTH SCIENCES, ANTALYA TRAINING AND RESEARCH HOSPITAL, DEPARTMENT OF CARDIOLOGY

https://orcid.org/0000-0002-0838-2037

Kunak

Tolga

AKDENIZ UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF CARDIOLOGY

03 27 2026

36 2026 1 6 10 21 2025 01 14 2026

1990

Genel Tıp Dergisi

Aim: This study aimed to evaluate the association between the tricuspid annular plane systolic excursion (TAPSE) systolic pulmonary artery pressure (sPAP) ratio, right ventricular (RV) S′ velocity, RV S′/sPAP ratio and, adverse clinical outcomes in hospitalized COVID-19 patients.Materials and Methods: A retrospective cohort of 100 adult patients hospitalized with laboratory-confirmed COVID-19 who underwent transthoracic echocardiography (TTE) was analyzed. Patients were classified into two groups according to clinical outcomes: adverse outcome (ICU admission, mechanical ventilation, ARDS, or in-hospital mortality) and favorable outcome. Echocardiographic parameters (TAPSE, sPAP, RV S′, TAPSE/sPAP, and RV S′/sPAP) were compared between groups, and receiver operating characteristic (ROC) curve analysis was performed to assess discriminative performance in this exploratory analysis.Results:Thirty-two patients experienced adverse outcomes. The TAPSE/sPAP ratio (0.44 ± 0.18 vs. 0.55 ± 0.22, p = 0.006), RV S′ velocity (9.17 ± 2.1 cm/s vs. 10.54 ± 2.1 cm/s, p = 0.004), and RV S′/sPAP ratio (0.28 ± 0.10 vs. 0.33 ± 0.08, p = 0.008) were significantly lower in the adverse outcome group. ROC analysis showed fair discriminative performance for TAPSE/sPAP, RV S′, and RV S′/sPAP with AUCs of 0.686, 0.691, and 0.753, respectively.Conclusion:TAPSE/sPAP, RV S′, and RV S′/sPAP are non-invasive echocardiographic markers associated with adverse outcomes in hospitalized COVID-19 patients. Their combined use may contribute to early risk stratification in an exploratory, hypothesis-generating context.

Amaç: Bu çalışmanın amacı, hastanede yatan COVID-19 hastalarında triküspit anüler düzlem sistolik ekskursiyonunun (TAPSE) sistolik pulmoner arter basıncına (sPAP) oranı, sağ ventrikül (RV) S′ hızı ve RV S′/sPAP oranı ile olumsuz klinik sonlanımlar arasındaki ilişkiyi değerlendirmektir.Gereç ve Yöntemler: Laboratuvar olarak doğrulanmış COVID-19 tanısı ile hastaneye yatırılan ve transtorasik ekokardiyografi (TTE) yapılan 100 erişkin hastadan oluşan retrospektif bir kohort analiz edilmiştir. Hastalar klinik sonuçlarına göre iki gruba ayrılmıştır: olumsuz sonuç (yoğun bakım ünitesine yatış, mekanik ventilasyon, akut solunum sıkıntısı sendromu [ARDS] veya hastane içi mortalite) ve olumlu sonuç. Ekokardiyografik parametreler (TAPSE, sPAP, RV S′, TAPSE/sPAP ve RV S′/sPAP) gruplar arasında karşılaştırılmış ve bu keşifsel analizde ayırt edici performansı değerlendirmek amacıyla alıcı işletim karakteristiği (ROC) eğrisi analizi yapılmıştır.Bulgular: Otuz iki hastada olumsuz klinik sonlanım gözlenmiştir. TAPSE/sPAP oranı (0,44 ± 0,18’e karşı 0,55 ± 0,22; p = 0,006), RV S′ hızı (9,17 ± 2,1 cm/sn’ye karşı 10,54 ± 2,1 cm/sn; p = 0,004) ve RV S′/sPAP oranı (0,28 ± 0,10’a karşı 0,33 ± 0,08; p = 0,008) olumsuz sonuç grubunda anlamlı derecede daha düşük bulunmuştur. ROC analizi, TAPSE/sPAP, RV S′ ve RV S′/sPAP için sırasıyla 0,686, 0,691 ve 0,753 AUC değerleri ile orta düzeyde ayırt edici performans göstermiştir.Sonuçlar: TAPSE/sPAP, RV S′ ve RV S′/sPAP, hastanede yatan COVID-19 hastalarında olumsuz klinik sonlanımlar ile ilişkili non-invaziv ekokardiyografik belirteçlerdir. Bu parametrelerin birlikte kullanımı, keşifsel ve hipotez oluşturmaya yönelik bir bağlamda erken risk sınıflandırılmasına katkı sağlayabilir.

COVID-19 Echocardiography Right ventricular function Prognosis TAPSE/sPAP RV S′/sPAP

COVID-19 Ekokardiyografi Sağ ventrikül fonksiyonu Prognoz TAPSE/sPAP RV S′/sPAP

N.A.

KAEK:535 22.07.2020

1. Kim J, Volodarskiy A, Sultana R, Pollie MP, Yum B, Nambiar L et al. Prognostic Utility of Right Ventricular Remodeling Over Conventional Risk Stratification in Patients With COVID-19. J Am Coll Cardiol. 2020;76(17):1965-1977.

2. Karagodin I, Carvalho Singulane C, Woodward GM, Xie M, Tucay ES, Tude Rodrigues AC et al. Echocardiographic Correlates of In-Hospital Death in Patients with Acute COVID-19 Infection: The World Alliance Societies of Echocardiography (WASE-COVID) Study. J Am Soc Echocardiogr. 2021;34(8):819-830.

3. Li Y, Li H, Zhu S, Xie Y, Wang B, He L et al. Prognostic Value of Right Ventricular Longitudinal Strain in Patients With COVID-19. JACC Cardiovasc Imaging. 2020;13(11):2287-2299.

4. D'Alto M, Marra AM, Severino S, Salzano A, Romeo E, De Rosa R et al. Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS. Crit Care. 2020;24(1):670.

5. Bursi F, Santangelo G, Barbieri A, Vella AM, Toriello F, Valli F et al. Impact of Right Ventricular-Pulmonary Circulation Coupling on Mortality in SARS-CoV-2 Infection. J Am Heart Assoc. 2022;11(4):e023220.

6. Warpechowski J, Olichwier A, Golonko A, Warpechowski M, Milewski R. Literature Review-Transthoracic Echocardiography, Computed Tomography Angiography, and Their Value in Clinical Decision Making and Outcome Predictions in Patients with COVID-19 Associated Cardiovascular Complications. Int J Environ Res Public Health. 2023;20(12):6123.

7. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14.

8. Naeije R, Manes A. The right ventricle in pulmonary arterial hypertension. Eur Respir Rev. 2014;23(134):476-487.

9. Vanderpool RR, Pinsky MR, Naeije R, Deible C, Kosaraju V, Bunner C et al. RV-pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension. Heart. 2015;101(1):37-43.

10. Guazzi M, Naeije R. Pulmonary Hypertension in Heart Failure: Pathophysiology, Pathobiology, and Emerging Clinical Perspectives. J Am Coll Cardiol. 2017;69(13):1718-1734.

11. Zochios V, Parhar K, Tunnicliffe W, Roscoe A, Gao F. The Right Ventricle in ARDS. Chest. 2017;152(1):181-193.

12. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-128.

13. Lazzeri C, Bonizzoli M, Batacchi S, Peris A. Echocardiographic assessment of the right ventricle in COVID -related acute respiratory syndrome. Intern Emerg Med. 2021;16(1):1-5.

14. Tsolaki V, Zakynthinos GE, Karavidas N, Vazgiourakis V, Papanikolaou J, Parisi K et al. Comprehensive temporal analysis of right ventricular function and pulmonary haemodynamics in mechanically ventilated COVID-19 ARDS patients. Ann Intensive Care. 2024;14(1):25. Published 2024 Feb 12. doi:10.1186/s13613-024-01241-1

15. Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I et al. Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study. Circulation. 2020;142(4):342-353.

16. Dandel M. Heart-lung interactions in COVID-19: prognostic impact and usefulness of bedside echocardiography for monitoring of the right ventricle involvement. Heart Fail Rev. 2022;27(4):1325-1339.

17. Anastasiou V, Papazoglou AS, Moysidis DV, Daios S, Barmpagiannos K, Gossios T et al. The prognostic impact of right ventricular-pulmonary arterial coupling in heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2024;29(1):13-26.

18. Bosch L, Lam CSP, Gong L, Chan SP, Sim D, Yeo D et al. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1664-1671.